Genome editing represents a paradigm shift from earlier genetic engineering approaches that inserted transgenes semi-randomly into host genomes. Modern genome editing tools, particularly CRISPR-Cas systems, allow researchers to target specific genomic loci with high precision. Earlier technologies like zinc finger nucleases and TALENs paved the way, but CRISPR dramatically lowered the barrier to entry by using simple RNA-DNA base pairing for target recognition rather than complex protein engineering.
The therapeutic potential of genome editing has attracted enormous investment. Companies like Mammoth Biosciences, co-founded by CRISPR pioneer Jennifer Doudna, are developing next-generation editing systems with improved specificity and delivery. Intellia Therapeutics and Editas Medicine have advanced CRISPR-based therapies into clinical trials, while Verve Therapeutics is pursuing in vivo base editing to treat cardiovascular disease. The 2023 approval of Casgevy, a CRISPR-based therapy for sickle cell disease developed by Vertex Pharmaceuticals and CRISPR Therapeutics, marked a watershed moment for the field.
Beyond therapeutics, genome editing is transforming agriculture, industrial biotechnology, and basic research. Companies like Pairwise are using CRISPR to develop improved crop varieties, while Inscripta and Synthego provide genome editing tools and reagents that have become essential infrastructure for the synthetic biology ecosystem. The continued discovery of novel CRISPR systems in nature, including compact Cas variants suitable for viral delivery, ensures that the toolkit will keep expanding.